Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BRAF NP_004324.2:p.V600X Clear all
Completed No phase listed Observational Results available

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

NCT01804140
View directory record Official record
Conditions
Multiple Myeloma, Neoplasms
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Sedona, Arizona • Tucson, Arizona • Burbank, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

NCT01954043
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib 150 mg twice a day (BID), Rabeprazole 40 mg once daily (OD), Rifampin 600 mg OD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Goodyear, Arizona • Dallas, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

NCT01286753
View directory record Official record
Conditions
Neoplasms
Interventions
Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Torrance, California • New Haven, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

NCT02608034
View directory record Official record
Conditions
Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions
Itraconazole, Rifampin, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 8:19 PM EDT
Terminated Phase 1 Interventional Results available

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

NCT03332589
View directory record Official record
Conditions
Malignant Melanoma, Brain Metastases
Interventions
E6201, E6201 plus dabrafenib
Drug
Lead sponsor
Spirita Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

NCT02684058
View directory record Official record
Conditions
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma
Interventions
Dabrafenib, trametinib, Carboplatin, Vincristine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 22, 2026, 8:19 PM EDT
Active, not recruiting Phase 2 Interventional

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

NCT02231775
View directory record Official record
Conditions
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Trametinib
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT05786924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
Interventions
S241656, FOLFOX6/FOLFOX7, FOLFIRI, Cetuximab, Panitumumab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Recruiting Early Phase 1 Interventional

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
Interventions
Encorafenib Pill, Binimetinib Pill, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Recruiting Phase 2 Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT07110246
View directory record Official record
Conditions
BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions
Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 25 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

NCT01767623
View directory record Official record
Conditions
Neoplasms
Interventions
Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

NCT01524978
View directory record Official record
Conditions
Multiple Myeloma, Neoplasms
Interventions
cetuximab, vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Tucson, Arizona • Aurora, Colorado • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jul 22, 2026, 8:19 PM EDT
Recruiting Phase 4 Interventional

Dabrafenib and/or Trametinib Rollover Study

NCT03340506
View directory record Official record
Conditions
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
4
States / cities
Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 4 Interventional Results available

An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

NCT01739764
View directory record Official record
Conditions
Neoplasms
Interventions
Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Rogers, Arkansas • Los Angeles, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 22, 2026, 8:19 PM EDT
Suspended Phase 1 Interventional

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167
View directory record Official record
Conditions
Solid Tumors
Interventions
JSI-1187, Dabrafenib
Drug
Lead sponsor
JS InnoPharm, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 8:19 PM EDT
Withdrawn Phase 2 Interventional

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

NCT03794297
View directory record Official record
Conditions
Erdheim-Chester Disease
Interventions
Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration, Trametinib Dimethyl Sulfoxide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

NCT01543698
View directory record Official record
Conditions
Solid Tumors Harboring a BRAF V600 Mutation
Interventions
LGX818, MEK162, LEE011
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

NCT02082665
View directory record Official record
Conditions
Cancer
Interventions
Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

NCT01677741
View directory record Official record
Conditions
Neoplasms, Brain
Interventions
Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jul 22, 2026, 8:19 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

NCT04190628
View directory record Official record
Conditions
Advanced Solid Tumor, BRAF V600 Mutation
Interventions
ABM-1310, Cobimetinib
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

NCT01436656
View directory record Official record
Conditions
Melanoma and Metastatic Colorectal Cancer
Interventions
LGX818
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

NCT01682083
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Placebos
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1 Interventional

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

NCT01787500
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
Interventions
Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Vemurafenib
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 22, 2026, 8:19 PM EDT